QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
Positive News Sentiment  
NASDAQ:INKT

MiNK Therapeutics - INKT Stock Forecast, Price & News

$2.29
0.00 (0.00%)
(As of 01/31/2023 05:19 PM ET)
Add
Compare
Today's Range
$2.21
▼
$2.29
50-Day Range
$2.13
▼
$2.65
52-Week Range
$1.09
▼
$4.32
Volume
25,948 shs
Average Volume
11,192 shs
Market Capitalization
$77.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

MiNK Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
205.7% Upside
$7.00 Price Target
Short Interest
Healthy
1.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.84) to ($0.87) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

328th out of 1,055 stocks

Biological Products, Except Diagnostic Industry

57th out of 170 stocks

See Top Rated MarketRank™ Stocks Here

INKT stock logo

About MiNK Therapeutics (NASDAQ:INKT) Stock

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Receive INKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

INKT Stock News Headlines

January 11, 2023 | finance.yahoo.com
MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference
December 22, 2022 | finance.yahoo.com
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2022 Earnings Call Transcript
January 31, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
November 17, 2022 | finance.yahoo.com
MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference
November 11, 2022 | msn.com
Massachusetts company MiNK Therapeutics working to make chemotherapy a thing of the past
November 10, 2022 | finance.yahoo.com
MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline
November 6, 2022 | finance.yahoo.com
Will MiNK Therapeutics (NASDAQ:INKT) Spend Its Cash Wisely?
November 3, 2022 | finance.yahoo.com
MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results
January 31, 2023 | PressReach (Ad)
Top Lithium Stock
Today's stock market report features a battery metal lithium stock with great potential.
October 20, 2022 | finance.yahoo.com
MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update
October 7, 2022 | benzinga.com
MiNK Selected for Five Presentations at Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting
October 5, 2022 | finance.yahoo.com
MiNK Therapeutics to Host R&D Event November 10, 2022
September 10, 2022 | seekingalpha.com
INKT MiNK Therapeutics, Inc.
August 31, 2022 | finance.yahoo.com
MiNK Therapeutics to Participate at Upcoming Investor Conferences
August 16, 2022 | finance.yahoo.com
Do Insiders Own Lots Of Shares In MiNK Therapeutics, Inc. (NASDAQ:INKT)?
August 9, 2022 | proactiveinvestors.com
MiNK Therapeutics pioneering iNKT cell therapies to treat cancer and other immune-mediated diseases
August 9, 2022 | finance.yahoo.com
MiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial Results
August 2, 2022 | finance.yahoo.com
MiNK Therapeutics to Participate at BTIG Biotechnology Conference
July 27, 2022 | finance.yahoo.com
MiNK Therapeutics to Report Second Quarter 2022 Financial Results and Business Update
June 18, 2022 | seekingalpha.com
ELMS, EMWP and EOSE among mid-day movers
May 25, 2022 | finance.yahoo.com
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
May 10, 2022 | finance.yahoo.com
MiNK Therapeutics Corporate Update and First Quarter 2022 Financial Report
May 9, 2022 | finance.yahoo.com
Here's Why We're Not Too Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Situation
April 27, 2022 | finance.yahoo.com
MiNK Therapeutics to Report First Quarter 2022 Financial Results and Business Update
April 9, 2022 | seekingalpha.com
CAN, LILM and AUR among mid-day movers
March 18, 2022 | seekingalpha.com
MiNK Therapeutics GAAP EPS of -$0.18 beats by $0.23
March 18, 2022 | finance.yahoo.com
MiNK Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
See More Headlines
Receive INKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

INKT Company Calendar

Last Earnings
11/03/2022
Today
1/31/2023
Next Earnings (Estimated)
3/17/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INKT
CUSIP
N/A
CIK
1840229
Web
www.minktherapeutics.com
Phone
212-994-8250
Fax
N/A
Employees
33
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+205.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.78)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-30,210,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-168.94%
Return on Assets
-78.30%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.33
Quick Ratio
1.33

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.71 per share
Price / Book
3.23

Miscellaneous

Outstanding Shares
33,790,000
Free Float
29,323,000
Market Cap
$77.38 million
Optionable
Not Optionable
Beta
-0.65

Key Executives

  • Dr. Garo H. Armen Ph.D. (Age 69)
    Exec. Chairman
  • Dr. Jennifer S. Buell Ph.D. (Age 47)
    Pres, CEO & Director
    Comp: $232.54k
  • Dr. Marcus Antonius van Dijk Ph.D. (Age 60)
    Chief Scientific Officer
  • Ms. Christine M. Klaskin (Age 56)
    Treasurer
    Comp: $20.02k
  • Mr. Patrick N. Jordan M.B.A.
    VP of Bus. Operations
  • Ms. Kimberly Ha
    Head of Investor Relations
  • Ms. Heather Boussios
    Gen. Counsel & Chief Compliance Officer
  • Joy Zhou Ph.D.
    VP & Head of CMC

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













INKT Stock - Frequently Asked Questions

Should I buy or sell MiNK Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MiNK Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" INKT shares.
View INKT analyst ratings or view top-rated stocks.

What is MiNK Therapeutics' stock price forecast for 2023?

1 Wall Street analysts have issued twelve-month price targets for MiNK Therapeutics' stock. Their INKT share price forecasts range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next year. This suggests a possible upside of 205.7% from the stock's current price.
View analysts price targets for INKT or view top-rated stocks among Wall Street analysts.

How have INKT shares performed in 2023?

MiNK Therapeutics' stock was trading at $2.61 on January 1st, 2023. Since then, INKT shares have decreased by 12.3% and is now trading at $2.29.
View the best growth stocks for 2023 here.

When is MiNK Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 17th 2023.
View our INKT earnings forecast.

How were MiNK Therapeutics' earnings last quarter?

MiNK Therapeutics, Inc. (NASDAQ:INKT) released its quarterly earnings data on Thursday, November, 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.04.

When did MiNK Therapeutics IPO?

(INKT) raised $43 million in an initial public offering (IPO) on Friday, October 15th 2021. The company issued 3,333,334 shares at a price of $12.00-$14.00 per share.

What is MiNK Therapeutics' stock symbol?

MiNK Therapeutics trades on the NASDAQ under the ticker symbol "INKT."

How do I buy shares of MiNK Therapeutics?

Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MiNK Therapeutics' stock price today?

One share of INKT stock can currently be purchased for approximately $2.29.

How much money does MiNK Therapeutics make?

MiNK Therapeutics (NASDAQ:INKT) has a market capitalization of $77.38 million. The company earns $-30,210,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

How can I contact MiNK Therapeutics?

The official website for the company is www.minktherapeutics.com. The company can be reached via phone at 212-994-8250 or via email at investor@minktherapeutics.com.

This page (NASDAQ:INKT) was last updated on 1/31/2023 by MarketBeat.com Staff